Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a consensus rating of “Buy” by the twenty-six brokerages that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $121.50.

A number of equities analysts recently commented on the company. JMP Securities increased their price target on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, September 20th. Barclays increased their price target on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, November 8th. Piper Jaffray Companies reissued an “overweight” rating and set a $110.00 price target (down from $126.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. FBR & Co assumed coverage on Alnylam Pharmaceuticals in a research note on Monday, October 30th. They set a “buy” rating and a $150.00 price target for the company. Finally, Cowen reissued an “outperform” rating and set a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd.

In other news, CEO John Maraganore sold 74,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total value of $9,387,640.00. Following the sale, the chief executive officer now directly owns 223,710 shares in the company, valued at $28,379,850.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the completion of the sale, the executive vice president now owns 45,201 shares in the company, valued at $5,490,113.46. The disclosure for this sale can be found here. Insiders sold a total of 237,330 shares of company stock valued at $30,520,815 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after buying an additional 815,270 shares during the period. Vanguard Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after buying an additional 759,295 shares during the period. BlackRock Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after buying an additional 441,957 shares during the period. Baillie Gifford & Co. raised its holdings in shares of Alnylam Pharmaceuticals by 2.9% in the second quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock worth $273,681,000 after buying an additional 96,805 shares during the period. Finally, Orbimed Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares during the period. Hedge funds and other institutional investors own 88.39% of the company’s stock.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down $2.69 during trading on Friday, reaching $131.96. The company had a trading volume of 777,200 shares, compared to its average volume of 642,433. Alnylam Pharmaceuticals has a 52 week low of $35.98 and a 52 week high of $147.63. The company has a market capitalization of $12,570.00, a price-to-earnings ratio of -25.14 and a beta of 2.98. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same period in the previous year, the company posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 24.8% on a year-over-year basis. sell-side analysts predict that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/05/alnylam-pharmaceuticals-inc-alny-given-consensus-recommendation-of-buy-by-brokerages.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.